DMT — Small Pharma Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- CA$48.67m
- CA$41.47m
Annual income statement for Small Pharma, fiscal year end - February 28th, CAD millions except per share, conversion factor applied.
2020 February 28th | 2021 February 28th | 2022 February 28th | 2023 February 28th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.159 | 0.078 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 0.903 | 5.73 | 20.6 | 24.7 |
| Operating Profit | -0.744 | -5.66 | -20.6 | -24.7 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -0.744 | -7.02 | -22.9 | -24.7 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.553 | -7.03 | -22.3 | -22.8 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.553 | -7.03 | -22.3 | -22.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.553 | -7.03 | -22.3 | -22.8 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.008 | -0.102 | -0.066 | -0.071 |
| Dividends per Share |